1. Introduction {#s0005}
===============

Chronic orofacial pain (COFP) disorders involve the head, face, and neck areas, notably the masticatory muscles, temporomandibular joint and associated structures. COFP is an umbrella term that encompasses several debilitating chronic syndromes affecting the orofacial region ([@bb0035]). To meet these broad classification terms, the painful syndrome must be present for \>12 weeks or persisting beyond expected healing time. As such, there are few epidemiological studies investigating the prevalence of all COFP disorders. It has been estimated that 7--11% of the population report COFPs ([@bb0030]; [@bb0460]).

Pain in the orofacial region is psychologically important, as it is implicated in vital biological functions such as eating, drinking, speech and sexual behavior ([@bb0400]). From a systems perspective, there are at least two mechanisms by which pain in the trigeminal system can potentially become chronic: (1) increased nociceptive drive along the trigeminal nociceptive pathway and/or (2) dysfunctional or aberrant descending modulation from supraspinal regions ([@bb0085]; [@bb0380]). Increased nociceptive drive is associated with increased activity in the trigeminal nociceptive pathway\'s central projections, including the trigeminal brainstem sensory nuclear complex, the ventroposteriormedial (VPM) and mediodorsal (MD) nuclei of the thalamus, and further cortical projections of the trigeminothalamic tract such as the primary somatosensory cortex (S1), the mid-cingulate cortex (MCC), and the dorsoposterior insula ([@bb0345]). Additionally, increased nociceptive drive is related to grey matter plasticity in healthy subjects ([@bb0375]). Over extended periods of time, this nociceptive barrage can drive maladaptive plasticity, and engender central sensitization ([@bb0185]). These processes lead to a disruption of function, and a diseased state.

Descending modulation of pain involves cortical and subcortical brain structures, typically described as including dorsolateral and medial prefrontal cortices (dlPFC, mPFC), anterior cingulate cortex (ACC), anterior insula, amygdala, and brainstem regions including the periaqueductal grey (PAG), and rostroventromedial medulla (RVM) ([@bb0070]). Involvement of these descending modulatory circuits has been reported in functional magnetic resonance imaging (fMRI) studies of placebo analgesia ([@bb0075]) and conditioned pain modulation ([@bb0040]; [@bb0450]). In the diseased state, it is thought that the pain modulatory circuits become dysfunctional, where endogenous analgesic brainstem changes occur ([@bb0235]) and maladaptive pain remains ([@bb0355]).

Here, we provide a quantitative meta-analysis of orofacial pain in health and in disease. COFPs investigated are non-odontogenic in origin and include musculoskeletal pain disorders (e.g., temporomandibular disorders (TMD)) and neuropathic orofacial pain disorders (e.g., trigeminal neuropathic pain (TNP), burning mouth syndrome (BMS)), as well as a number of other orofacial syndromes. A meta-analysis of experimental pain in healthy subjects can provide an understanding of spatially consistent brain activations in response to acute nociceptive stimulation in the orofacial region. Furthermore, separate meta-analyses of COFP structure and function may highlight consistent structural and functional abnormalities, respectively, in chronic pain. A recent meta-analysis of experimental dental pain found consistent activation in the dlPFC ([@bb0215]). Another meta-analysis investigating TMD and TNP found consistent structural and functional abnormalities in the thalamus and S1 ([@bb0200]). Several studies have found structural and functional abnormalities in COFP, but their findings are divergent. As such, a quantitative meta-analysis including phenotypically different COFP disorders can provide a directionality for future studies investigating pain mechanisms in COFP.

Therefore, the aim of the current study was to perform three coordinate-based meta-analyses: (1) functional response to experimental pain in the orofacial region in healthy subjects; (2) functional and (3) structural abnormalities in COFP disorders. We hypothesized that the brain activations during experimental orofacial pain, compared to baseline conditions, would show consistent activation along the trigeminal nociceptive pathways, and descending modulatory pathways. In our functional and structural meta-analysis of COFP, we hypothesized that trigeminal nociceptive and pain modulatory brain regions would show consistent abnormalities across COFP disorders, in COFP patients compared to healthy controls.

2. Methods {#s0010}
==========

Our study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2015 guidelines and the PRISMA checklist is reported in Supplementary Table A.1 ([@bb0260]).

2.1. Article selection criteria {#s0015}
-------------------------------

We selected articles using the following exclusion criteria: 1) non-human animal studies; 2) absence of standardized stereotactic (i.e. Montreal Neurological Institute (MNI) or Talairach ([@bb0370])) brain coordinates; 3) overlapping data across studies, such as reviews 4) region of interest (ROI) analyses; 5) case reports; 6) diagnostic or surgical MRI; 7) diffusion tensor imaging; 8) studies of headache or migraine as primary disorders; 9) studies of other chronic pain conditions; 10) studies without a baseline for experimental pain studies or control groups for COFP studies; 11) studies not written in the English language; and 12) not peer-reviewed studies. We also excluded functional connectivity and cortical thickness analyses. Hence, only voxel-based morphometry (VBM) and fMRI, including blood-oxygen-level-dependent (BOLD) and positron-emission tomography (PET) studies reporting standardized whole-brain coordinates were used for the purpose of this study. Studies of headache and/or migraine were excluded because our meta-analyses focused on musculoskeletal and neuropathic orofacial pain, rather than craniofacial pain. In addition to our exclusion criteria that are meant to reduce experimental bias, we carefully screened for the risk of bias in terms of conflicts of interest on an individual study scale. All authors of the studies included in our study have no conflict of interests. Risk of bias across studies may affect our ALE analyses since some authors share the same collaborations and data might have been transferred from one study to the other. Authors do not claim such data transfers, and we could not have excluded such articles based on these assumptions. We assigned a quality score for each article selected based on a modified version of Downs and Black\'s checklist for quality assessment ([@bb0110]; Supplementary Table A.2) as reported by Burns and colleagues ([@bb0065]). A maximum quality score based on external and internal validity is 20. Finally, two investigators (LA, MM) independently reviewed the exclusion criteria for article eligibility.

2.2. Database search {#s0020}
--------------------

A summary of our article selection from the database search on 22 March 2018 is provided according to the PRISMA guidelines (see [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). We performed two separate systematic searches across four literary databases through all articles until 22 March 2018: ISI Web of Science, PubMed, Embase and Medline. We used the following keyword search expression for functional studies of experimental pain and COFP disorders across all databases: *"((orofacial OR (trigeminal OR masseter OR burning mouth syndrome OR BMS OR temporomandibular OR TMD)) AND pain AND (fMRI OR functional magnetic resonance imaging OR functional MRI OR (BOLD OR blood oxygen level dependent) OR (PET OR positron emission tomography) OR (ASL OR arterial spin labelling)))".* In addition, we used the following keyword search terms to identify structural studies of COFP across all databases: "*((orofacial OR (trigeminal OR masseter OR burning mouth OR BMS OR temporomandibular OR TMD)) AND Pain AND (DBM OR deformation based morphometry OR (VBM OR voxel-based morphometry OR DARTEL) OR grey matter OR gray matter OR sMRI))".*Fig. 1Article selection for functional studies. Flow diagram according to PRISMA guidelines for functional MRI article selection procedures.Fig. 1Fig. 2Article selection for structural studies. Flow diagram according to PRISMA guidelines for structural MRI (grey matter) article selection procedures.Fig. 2

2.3. Activation/anatomical likelihood of estimation (ALE) meta-analysis {#s0025}
-----------------------------------------------------------------------

Our activation/anatomical likelihood estimation (ALE) based meta-analysis was performed using the GingerALE software (v2.3.6). Briefly, the purpose of the ALE algorithm is to compute whole-brain standardized coordinates into a voxel-based statistical value, which projects the probability of activation or anatomical alterations of brain regions ([@bb0130]).

2.4. Dataset foci {#s0030}
-----------------

Peak voxel brain coordinates (X, Y, Z) of healthy subjects under noxious stimuli and pain-free baseline condition, and COFP patients reporting abnormal grey matter structure and brain region activation, were used as data. Our structural meta-analysis included foci from studies investigating grey matter volume and concentration (GMV/GMC). Our functional meta-analysis included foci from studies investigating cerebral blood flow.

All data were extracted manually from each study and organized in text files according to its specific contrast and subject number ([@bb0125]). First, all brain coordinates (foci) reported in Talairach space were converted into MNI space using the algorithm "Brett: Talairach to MNI" ([@bb0045]). Each group of foci included the number of subjects for smoothing estimation purposes ([@bb0130]). Furthermore, foci were organized into six separate datasets according to subject group and their findings in terms of brain region activity and GMV/GMC as follows: (1) greater brain region activation in response to experimental pain compared to baseline control in healthy subjects; (2) lesser brain region activation in response to experimental pain compared to baseline control in healthy subjects; (3) GMV/GMC increase in COFP patients compared to a control group; (4) GMV/GMC increase in COFP patients compared to a control group; (5) greater brain region activity in COFP patients compared to a control group; (6) lesser brain region activity in COFP patients compared to a control group. Data was confirmed by two investigators, independently (LA, MM). Therefore, datasets 1 and 2 identify consistent brain region of activation in response to acute experimental orofacial pain; datasets 3 and 4 identify consistent GMV/GMC abnormalities between COFP and healthy participants; and datasets 5 and 6 identify consistent brain activity abnormalities between COFP and healthy participants.

2.5. Dataset analysis {#s0035}
---------------------

We used the single dataset analysis module in the GingerALE software to compute each of the contrasts, as described elsewhere ([@bb0130]). A total of six single dataset analyses were performed. We employed the revised Eickhoff algorithm ([@bb0125]) for the functional and structural COFP meta-analyses. For the acute experimental pain meta-analysis, we used Turkeltaub\'s Non-Additive algorithm to potentially minimize effects within a subject group and between experiments ([@bb0390]). Briefly, each analysis consisted of four steps performed automatically by the GingerALE software: 1) calculating ALE scores, 2) deriving a null distribution, 3) statistical thresholding and 4) correction for multiple comparisons using cluster-based thresholding. An ALE score was generated for each of the foci to produce a Modeled Activation (MA) map. All MA maps were calculated by finding the maximum value with the "random effects" selection, which permits the generalization of results ([@bb0125]). All the MA maps were united to form the unthresholded ALE map. Then, the Gaussian null distribution was used to calculate the ALE statistic, which attributes a *p* value to every ALE score, and forms the thresholded ALE image. The cluster analysis was then performed on the thresholded ALE image with the cluster-level inference algorithm at *p* \< .05, based on 1000 permutations, with a cluster-forming threshold of *p* \< .005. We also conducted the same analysis using a more conservative cluster-forming threshold of *p* \< .001 for comparative purposes. The resulting cluster-corrected maps were visualized with the Mango software (v4.0.1) ([rii.uthscsa.edu](http://rii.uthscsa.edu){#ir0005}/mango) and the multiple axial slice images were created using MRIcron software ([@bb0330]).

3. Results {#s0040}
==========

3.1. Article search {#s0045}
-------------------

Our functional database search resulted in 2467 articles and 20 articles were included ([Fig. 1](#f0005){ref-type="fig"}). Our structural database search resulted in 560 articles and ten structural COFP articles were selected ([Fig. 2](#f0010){ref-type="fig"}). In studies of healthy subjects, 12 functional studies report brain region activation in response to experimental noxious stimuli ([Table 1](#t0005){ref-type="table"}). In COFP studies, ten structural studies are shown in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"} and eight functional studies are shown in [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}.Table 1Summary of experimental orofacial pain studies.Table 1ReferenceNW/MAge (mean ± SD or range in years)Imaging ModalityStimulationQS (/20)ModalityBody Part[@bb0205]169/727.37 ± 11.2BOLDElectricalR Upper central incisor16[@bb0210]159/626.3 ± 11.2BOLDElectricalR Upper incisor16[@bb0280]128/828.8 ± 7.7BOLDThermalR Maxilla18[@bb0060]218/1320--44BOLDElectricalbilat Maxillary canines/central incisors18[@bb0285]17/15/208/2019--52BOLDChemical/MechanicalR Masseter/cutaneous/lip16[@bb0290]17/158/2219--52BOLDChemicalR Masseter/cutaneous15[@bb0300]113/823.3 ± 2.0BOLDElectricalR Forehead (trigeminal nerve)16[@bb0165]2313/1044/61[a](#tf0005){ref-type="table-fn"}BOLDChemicalR Nostril (trigeminal nerve)15[@bb0275]12/90/1230 ± 7BOLDChemical/ThermalL Maxillary division (trigeminal nerve)16[@bb0055]1411/328.9 ± 4.1BOLDThermalR Below lower lip16[@bb0095]99/026.2 ± 6.9BOLDThermalL Masseter16[@bb0190]104/621--25rCBFChemical/MechanicalR Masseter16[^1][^2]Table 2Summary of VBM studies of COFP.Table 2ReferencePatientsHealthy controlsGrey matter findingsQS (/20)COFPNW/MAge (mean ± SD in years)NW/MAge (mean ± SD in years)[@bb0385]CTN (right)3620/1658.0 ± 7.71915/455.6 ± 6 8.2GMV16CTN (left)2618/859.0 ± 6.6GMV[@bb0415]CTN3822/1655.87 ± 8.383822/1655.89 ± 8.06GMV17[@bb0195]TN2813/1545.86 ± 11.172813/1544.89 ± 7.67GMV19[@bb0365]BMS127/559.4 ± 12.11310/359.0 ± 3.4GMC17[@bb0180]BMS99/054.0 ± 7.799/056.0 ± 8.2GMV19[@bb0305]TN6036/2462.0 ± 13.24918/2161.8 ± 9GMV19[@bb0135]TMD99/025.4 ± 2.599/024.8 ± 1.4GMV17[@bb0140]PTN2117/454.7 ± 2.13024/653.6 ± 3.2GMV19[@bb0335]PIFP119/252.2 ± 8.9119/251.3 ± 8.6GMV16[@bb0440]TMD1414/038.0 ± 13.71515/0age-matchedGMV17[^3]Table 3Grey matter findings in COFP studies.Table 3COFPS1ThalInsulaCingulatePFCOtherReference*COFP \> Controls*BMSR dlPFCR PCL/Ti[@bb0365]R Hc[@bb0180]DYSR S1bilat MTG[@bb0365]TMDL VP, R VLR aINSR vlPFCR GP/ML/Pu, bilat MCP/VMN/VMSN[@bb0440]CTNR SPL[@bb0415], [@bb0420]PTNR pINS[@bb0140]  *Controls \> COFP*BMSL PCC/sACCL Cereb[@bb0365]L mPFC[@bb0180]DYSR sACC/MCCR pre-SMA, L mOFC[@bb0365]PIFPL S1L pINSbilat aMCCL dlPFC/FP, R PMCL STG, bilat M1[@bb0335]R aINSR PCC, L pACCL vlPFC/dlPFCR MTG/ParaHc/PCu, bilat STG[@bb0135]R S1[@bb0440]CTNR VP, L MDbilat SMAbilat Cereb, R NAc, L Hypo/IFG[@bb0385] (right CTN)bilat pulvinarL SMAbilat Cereb, L VS/Pu/IFG[@bb0385] (left CTN)R pINSL ACC/MCCR S2, bilat ITG, L STG/ M1/PMC[@bb0415], [@bb0420]TNL sACCR Cereb/Fus, L CN, bilat MTG/ParaHc/STG[@bb0195]L S1R OFC[@bb0305]PTNL S1bilat ThalL aINSR NAc, L Pu[@bb0140][^4]Table 4Summary of functional COFP studies.Table 4ReferencePatientsHealthy controlsfMRI analysis methodStimulationQS (/20)COFPNW/MAge (mean ± SD or S.E.M. in years)Pain intensity (/10)NW/MAge (mean ± SD or S.E.M. in years)Rest/taskPain intensity (/10)Body Part[@bb0415]CTN1710/762.53 ± 7.416.12 ± 1.501911/861.75 ± 6.02fALFFRest16[@bb0455]ITN239/1459.6 ± 12.58.1 ± 1.62311/1263.1 ± 9.8ReHo and fALFFRest16[@bb0010]NP1714/350.6 ± 2.84.12 ± 2.614433/1145.9 ± 2.0TaskChemicalHealthy: 5R Masseter18[@bb0410]ITN1710/763.41 ± 7.256.12 ± 1.501910/962.53 ± 7.41ReHoRest19[@bb0150]TMD2314/922.4 ± 3.647.3 ± 21.4[a](#tf0010){ref-type="table-fn"}2011/923.1 ± 2.4fALFFRest17[@bb0425]TMD1717/035.2 ± 11.64.41 ± 1.771717/034.0 ± 9.9TaskStroop task19[@bb0295]TMD1313/028.7 ± 7.62.41212/028.8 ± 7.9TaskElectricalTMD[b](#tf0015){ref-type="table-fn"}: 32.0 ± 15.4R Index18Healthy[b](#tf0015){ref-type="table-fn"}: 19.2 ± 12.5[@bb0005]BMS88/049.1 ± 10.15.6 ± 1.988/050.3 ± 12.3TaskThermalBMS: 7.1 ± 1.4 Healthy: 5.8 ± 1.8R Masseter18[^5][^6][^7]Table 5Functional findings in COFP studies.Table 5COFPS1ThalInsulaCingulatePFCOthersReference*COFP \> controls*BMSR aMCCbilat PCu[@bb0005]CTNL pINSL dlPFC/latFPR Fus/TPJ, L TP/SPL/MTG, bilat Cereb[@bb0415], [@bb0420]ITNR ACCL dlPFCR Cereb/PCu, L MTG/SFG[@bb0455] (Reho)bilat Pu[@bb0455] (fALFF)R ThalR IPL/Fus, L SPL[@bb0410]PTNL S1L VP/MD/VLL dpINS, R mid INSL MCCbilat dlPFCR STn, L dlPons, bilat Cereb[@bb0010]TMDL S1R aINS/pINSR aMCC, L PCC/RSC /sACC, bilat pACCR dlPFC, bilat PMCv/ mFPR CN/STN, L Fus/IPL/ParaHc, bilat Amyg/SPL/MTG[@bb0425]bilat S1bilat ThalL pINSbilat aMCCL Amyg/PT, bilat A1/S2[@bb0295]  *Controls \> COFP*BMSR S1bilat MDR dlPFCbilat Cereb[@bb0005]CTNL dlPFCR Fus/Cu/ITG, L Cereb/MOG, bilat PCu[@bb0415], [@bb0420]ITNL pINSR Cereb[@bb0455] (Reho)R Cereb, L V2[@bb0455] (fALFF)R ParaHc, L Amyg/Cereb[@bb0410]PTNR dlPFC[@bb0010]TMDR OFC, L latFP/SMAL M1[@bb0150]bilat dlPFCR MTG[@bb0425]bilat S1L mid INSL S2[@bb0295][^8]

3.2. Methodological quality {#s0050}
---------------------------

Quality scores for each study are reported in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 4](#t0020){ref-type="table"}. Average quality scores for functional experimental pain, structural and functional COFP studies were 16.17 ± 0.94, 17.60 ± 1.27 and 17.63 ± 1.19 (mean ± standard deviation), respectively, from a maximum score of 20. Some studies did not report sufficient statistical calculations on demographics, which accounted for one point. In addition, none of the studies reported performing sample size calculations a priori.

3.3. Dataset results {#s0055}
--------------------

Six separate datasets resulted from our data extraction with their respective total number of foci, subjects and experiments:•Brain region activation during experimental pain \> baseline in healthy subjects: 260 foci results from 198 total subjects in 14 experiments;•Brain region activation during experimental pain \< baseline in healthy subjects: 80 foci resulted from 86 total subjects in 6 experiments;•GMV/GMC in COFP patients \> healthy controls: 21 foci resulted from 199 total subjects in 5 experiments;•GMV/GMC in COFP patients \< healthy controls: 66 foci resulted from 504 subjects in 11 experiments.•Brain activity in COFP patients \< healthy controls: 38 foci resulted from 343 total subjects in 9 experiments;•Brain activity in COFP patients \> healthy controls: 109 foci resulted from 300 subjects in 8 experiments;

3.4. ALE Meta-analyses {#s0060}
----------------------

### 3.4.1. Experimental orofacial pain stimuli in healthy subjects {#s0065}

Our ALE meta-analysis of healthy individuals subjected to experimental pain in the orofacial area showed consistently greater brain region activation in six regional clusters: bilateral MD extending to the posterior thalamus, bilateral posterior MCC (pMCC), bilateral secondary somatosensory cortices (S2), the right posterior parietal cortex (PPC) extending into S1 and the right insula, significant at cluster-corrected *p* \< .05 and cluster-forming threshold of *p* \< .005 ([Fig. 3](#f0015){ref-type="fig"}; [Table 6](#t0030){ref-type="table"}). We also found similar results at a more conservative cluster-forming threshold of *p* \< .001 with five clusters of activation, which included bilateral thalami, the right insula, the right PPC, the left S2 and the left pMCC (Supplementary Table A.3; Supplementary Fig. A.1). The right pMCC and the right S2 did not survive at the cluster-forming threshold *p* \< .001. In addition, we found decreased brain activity in the hand region of the right S1 and primary motor cortex (M1) in response to nociceptive stimulation in the orofacial region at both thresholds, *p \<* .005 and *p \<* .001. A distinction in functional variations is observed in the region of S1; an increase is found in the orofacial region of S1 as opposed to a decrease in the hand region of S1.Fig. 3(A) Significant ALE effects of functional MRI studies of healthy subjects during experimental orofacial pain. The functional MRI meta-analysis in healthy subjects identified significant ALE effects in bilateral thalami, bilateral posterior mid-cingulate cortex (pMCC) and bilateral secondary somatosensory cortices (S2), the right PPC extending to the primary somatosensory cortex (S1), the right insula and the primary motor cortex (M1) in healthy subjects during experimental pain (Exp.) (cluster-corrected *p* \< .05 and cluster-forming threshold of *p* \< .005). (B) Axial slices of thalamic activity in healthy subjects during experimental orofacial pain. Thalamic activation cluster from the meta-analysis of experimental studies (cluster-corrected *p* \< .05, cluster-forming threshold *p* \< .005).Fig. 3Table 6ALE results of functional experimental orofacial pain.Table 6Brain regionsBAALE ValueMNI coordinatesCluster Size (mm^3^)XYZ*Experimental pain \> baseline control*L Thalamus0.033−10−2064880 R Thalamus0.0226−186R Insula130.0184818−83336 R mid/pINS0.015420−6 R aINS130.0124210−6 R pINS0.00942−6−6 R STG380.009402−18R PPC/S1400.01550−32502240 R PPC400.01346−3854 R S120.01054−2244 R S130.00954−1440L S2410.017−58−20142176 L S2400.010−58−2634R pMCC310.0172−8462056 L pMCC240.015−2−248 pMCC240.0120448 L SMA60.009−2−656 R pMCC240.0094−238R S2400.01454−30241696 R PPC400.01366−3424  *Experimental pain \< baseline control*R S130.01028−28561792 R M140.00940−1862 R S130.00948−2060[^9][^10]

3.5. COFP patients vs. healthy controls {#s0070}
---------------------------------------

### 3.5.1. Meta-analysis of structural brain imaging studies {#s0075}

Our ALE meta-analysis of COFP compared to healthy controls found consistently greater GMV/GMC in one cluster which included the right thalamus (ventral lateral (VL)) and posterior putamen ([Fig. 4](#f0020){ref-type="fig"}; [Table 7](#t0035){ref-type="table"}). These findings are significant at a cluster-corrected *p* \< .05 and a cluster-forming threshold of *p* \< .005, but not at *p* \< .001.Fig. 4(A) Significant ALE effects of structural COFP studies. The structural MRI (grey matter) COFP meta-analysis identifies structural GMV/GMC increase in the right thalamus and putamen in COFP patients compared to healthy subjects, significant at *p* \< .05 (cluster-corrected, cluster-forming threshold of *p* \< .005). (B) Axial slices of structural thalamic abnormalities in COFP patients. Representation of the thalamic activation cluster from the meta-analysis of structural chronic pain studies (cluster-corrected *p* \< .05, cluster-forming threshold *p* \< .005).Fig. 4Table 7ALE results of COFP studies.Table 7Brain regionsALE ValueMNI CoordinatesCluster Size (mm^3^)XYZStructural COFP studies*COFP patients (GMV/GMC) \> Controls (GMV/GMC)*R Thalamus0.01216−1021640 R posterior Putamen0.00928−1210  Functional COFP studies*COFP patients \> Controls* L Thalamus0.026−6−2481080*COFP patients \< Controls*L pINS0.013−46−4101336 L pINS0.010−42−126[^11][^12]

### 3.5.2. Meta-analysis of functional brain imaging studies {#s0080}

Our ALE meta-analysis of COFP patients in comparison with healthy controls found that COFP patients had consistently greater brain function (activity or resting-state fluctuations) in the left medial and posterior thalamus (MD, pulvinar) in COFP and less function in the left posterior insula in COFP compared to controls ([Fig. 5](#f0025){ref-type="fig"}, [Table 7](#t0035){ref-type="table"}). Notably, the region of the thalamus overlaps with the finding in experimental orofacial nociceptive stimulation. These findings are significant at a cluster-corrected *p* \< .05 and a cluster-forming threshold of *p* \< .005. At a more conservative threshold of *p* \< .001, only the left posterior insula cluster survives along with an additional cluster in the left cerebellum (Supplementary Fig. A.2).Fig. 5(A) Significant ALE effects of functional COFP studies. The functional MRI COFP meta-analysis identified significant ALE effects in the left posterior thalamus and left posterior insula of COFP patients compared to healthy controls, significant at *p* \< .05 (cluster-corrected, cluster-forming threshold of *p* \< .005). (B) Axial slices of functional thalamic abnormalities in chronic orofacial pain patients. Thalamic cluster from the meta-analysis of functional MRI COFP studies (cluster-corrected *p* \< .05, cluster-forming threshold *p* \< .005).Fig. 5

4. Discussion {#s0085}
=============

COFPs are heterogeneous disorders but have one chief symptom in common: chronic pain in the head and neck region. Finding convergence of brain regions of activation across COFPs would suggest overlap in the neural mechanisms of the common feature of these disorders. We performed three ALE meta-analyses to identify consistent (1) brain regions of activation in response to experimental orofacial pain in healthy subjects and (2) abnormal grey matter and (3) abnormal brain function in COFP. We found the thalamus across all meta-analyses, suggesting a key role in orofacial pain, notably in COFP pathophysiology.

4.1. Experimental orofacial stimuli {#s0090}
-----------------------------------

The first key set of findings in this study are related to experimental orofacial pain in healthy participants. We identified consistent activations along the ascending trigeminal pathway, including: thalamus, S1, S2, PPC, pMCC, insula, i.e. regions typically reported in pain neuroimaging ([@bb0115]). We also found less activation in the hand region of S1 and M1. The sensory-discriminative dimension (location, duration, and intensity) of pain is thought to be processed in somatosensory regions, including S1, S2 and the PPC ([@bb0310]). S1 and S2 receive orofacial nociceptive input from VPM, among other regions ([@bb0085]; [@bb0435]). Our findings are consistent with a previous quantitative meta-analysis of experimental dental pain, which reported S1 activation of the orofacial region ([@bb0215]). The contributing foci to the right orofacial S1 cluster originate from studies which applied right facial noxious stimuli. Although we would expect bilateral S1 activation, as 20% of ascending fibers in the trigeminal tract remain ipsilateral to the innervated facial area ([@bb0325]; [@bb0345]), we observed only ipsilateral activation. We also found less activation in the hand region of S1 and M1, suggesting it could be related to enhancing the spatial acuity of the stimulus. In addition, we observed activation in the PPC---a higher order somatosensory processing region, which has suggested to be a suitable target for pain intensity management ([@bb0280]).

We further found consistent activation salience processing regions: pMCC and insula ([@bb0340]). The pMCC finding is in line with an electrophysiological study in humans, which identified nociceptive-responsive cells in this region ([@bb0160]). Additionally, evidence from tracing studies in non-human primates show that the spinothalamic tract projects to the MCC via the MD ([@bb0120]). Indeed, we also observed activation in a large region of the thalamus, including MD, in response to experimental orofacial nociceptive stimulation. There are several roles ascribed to the MCC in the context of pain. For example, some suggest it is implicated in encoding emotional value of pain ([@bb0320]), others in nocifensive behaviours ([@bb0255]). Therefore, this region could act as an interface between the cognitive and affective dimensions of pain and the motor response to it ([@bb0315]; [@bb0350]). This meta-analysis also identified activation in the insula, a region referred to as a multidimensional integrator for pain ([@bb0050]). Several studies have suggested that the posterior aspect of the insula encodes nociceptive stimulus properties (i.e. pain intensity) ([@bb0080]; [@bb0240]; [@bb0270]), while the anterior insula is thought to be implicated in the cognitive-motivational dimension of pain ([@bb0020]). These findings are helpful in understanding the regions activated by nociceptive stimulation of the orofacial region in healthy subjects.

4.2. COFP disorders {#s0095}
-------------------

Acute pain states resolve in most individuals, but in some cases, pain may persist beyond its expected healing duration, becoming chronic. Thus, we reviewed the structural and functional brain imaging literature in COFP to identify convergent patterns of brain abnormalities in these disorders. An increasing number of studies have reported structural brain abnormalities in chronic pain populations ([@bb0085]). Our meta-analysis found consistently greater GMV/GMC in the right VL thalamus and posterior putamen of patients compared to controls across COFP studies. These regions were identified in a previous TMD study ([@bb0440]), and were positively correlated with TMD duration ([@bb0250]). In contrast, one other study did not find significant GMV abnormalities in TMD ([@bb0140]). Such disparities across studies may be related to statistical differences, including differences in the sample size of the studies. Our ALE finding however, weighted by a cumulative sample size, showed an increase in thalamic GMV/GMC. Evidence from a repeated experimental pain model in healthy individuals suggests that GMV increases are driven by increases in nociceptive input ([@bb0375]). In the current study, however, we could not discern whether GMV/GMC abnormalities in COFP are pre-existing or a result of persistent nociceptive drive.

We identified convergent brain function in COFP using the quantitative ALE analysis, which was only previously qualitatively established in TN and TMD studies ([@bb0200]). Our meta-analysis of functional COFP studies found consistently greater function -- defined as greater activation in contrast BOLD studies, and abnormal BOLD variability in resting-state fMRI -- in the medial and posterior thalamus (MD, pulvinar) and lesser function in the posterior insula of patients compared to healthy controls across COFP studies. This MD thalamus region also overlaps with the thalamic cluster we reported in our meta-analysis of orofacial stimulation in healthy subjects. Together, these findings highlight that COFP patients either have increased nociceptive drive from the periphery or central sensitization. Our results are in line with a qualitative meta-analysis of trigeminal disorders which reported greater activation in the thalamus and S1 in trigeminal neuropathic pain ([@bb0200]), painful trigeminal neuralgia (PTN) ([@bb0025]) and trigeminal neuralgia ([@bb0265]). Previous studies show consistent thalamic hyperactivity may result from persistent pain ([@bb0010]), increased thalamocortical oscillatory activity within the ascending pain pathway ([@bb0010]; [@bb0175]) or metabolite changes ([@bb0410]). However, there has been growing evidence of altered thalamic activity in PTN associated with significant reduction in gamma-aminobutyric acid (GABA) content, an inhibitory neurotransmitter, and reduced cerebral blood flow in response to persistent pain ([@bb0140]; [@bb0145]; [@bb0155]). Interestingly, a previous study evaluated altered thalamic neuronal activity in patients with neuropathic pain and reported blood flow increase in the early stages of the disease and decrease as the condition became chronic ([@bb0395]). We also report that COFP patients have less function in the posterior insula, a region typically observed in experimental pain studies, and in line with previous evidence of insular abnormality in TN ([@bb0455]) and TMD ([@bb0295]). We also did not identify consistent differences across other brain regions that are observed in chronic pain, including S1, S2 and the mid- and anterior cingulate cortex ([@bb0015]), although some of the studies did report activation in these regions. Indeed, mechanistic differences among neuropathic pain compared to non-neuropathic pain conditions have yet to be elucidated and more COFP studies would be required for that direct comparison.

4.3. Study limitations {#s0100}
----------------------

There are several limitations to our study. First, we limited our search to orofacial pain, and have excluded headache and migraine disorders to focus on COFPs. As a result, our study may not be representative of the field as a whole.

The experimental orofacial pain meta-analysis did not analyze studies according to stimulation laterality or noxious stimulus modality. Recent studies have led us to hypothesize bilateral activation of regions associated with orofacial nociceptive processing ([@bb0225]; [@bb0285]; [@bb0290]). In addition, a study reported that different stimulus modalities have both overlapping and unique patterns of brain activations ([@bb0170]). Our study could not further investigate these unique patterns, given the paucity of experimental orofacial pain studies.

The complexity of COFP disorders lies not only in the plurality of their etiologies, but the heterogeneity of the patient population, co-morbidities and medication usage. These factors were taken into consideration within their specific studies. The disorders included in COFP meta-analyses were heterogeneous in nature; which is both a strength and limitation of our meta-analysis. We did not separate studies based on disease etiology (neuropathic vs. non-neuropathic), study condition (task vs. rest) or grey matter metric (GMV vs. GMC). Our analysis is not aimed at drawing out these differences as there are not sufficient studies to draw such inferences. Rather, by combining these COFPs in our meta-analysis we can identify transdiagnostic abnormalities in COFPs, which provide both mechanistically relevant information, and potential therapeutic targets.

The outcomes of the functional COFP meta-analysis will be affected by the heterogeneity of the experimental designs of the studies included. Indeed, this is precisely the aim of a meta-analysis---to identify common activation despite experimental heterogeneity. Here, the functional COFP studies did not all employ matched stimulus intensities between the two groups, although one did. The unmatched stimulus intensities could bias brain activation differences observed.

Furthermore, our systematic search selectively included whole-brain analyses to prevent false negative or positive results, as the null-hypothesis of the ALE method presumes a uniform distribution of foci activation throughout the whole brain. Also, the ALE method does not include in its algorithm the heterogeneity in statistical thresholding methods among studies. Rather, studies are weighted by sample size. Therefore, studies with varying levels of evidence are not weighted differently. Our systematic search did not discriminate between uncorrected and stringent statistical thresholding approaches. Among the studies selected, ten did not account for multiple comparison analyses, and reported findings at an uncorrected *p-*value ([@bb0095]; [@bb0135]; [@bb0150]; [@bb0165]; [@bb0205]; [@bb0210]; [@bb0300]; [@bb0335]; [@bb0365]; [@bb0415]). We have, however, presented a quality score that accounts for the correction method. Nonetheless, these studies may bias our final ALE results.

Finally, our COFP findings were only significant at *p \<* .005, likely due to the paucity of imaging data (with the exception of the functional analysis findings of the insula and cerebellum, which were significant at *p \<* .001). As such, our study allowed us to determine which brain regions are abnormal across conditions as conducted in a previous ALE analysis ([@bb0100]). Accordingly, ALE meta-analyses require an approximate 8--15 experiments per contrast for robust statistical power ([@bb0360]; [@bb0405]), suggesting that our contrasts of 6 and 5 experiments should be interpreted with caution.

5. Conclusion {#s0105}
=============

In conclusion, our coordinate-based meta-analysis of experimental acute pain in healthy subjects is convergent with previous studies that show sensory, affective and cognitive systems are implicated in acute orofacial pain. In addition, we present the first coordinate-based meta-analysis in COFP disorders, excluding headache/migraine, to show directionality in functional and structural abnormalities across COFPs.

Appendix A. Supplementary data {#s0130}
==============================

Supplementary materialImage 1
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[^1]: Abbreviations: *bilat* bilateral, *BOLD* functional magnetic resonance blood-oxygen-level dependent imaging, *L* left, *M* men, *QS* quality score, *R* right, *rCBF* positron-emission tomography resting cerebral blood flow*, W* women.

[^2]: Only mean age for women and men (without standard deviation) is reported.

[^3]: Abbreviations: *BMS* burning mouth syndrome, *COFP* chronic orofacial pain, *CTN* classic trigeminal neuralgia, *GMC* grey matter concentration, *GMV* grey matter volume, *M* men, *PIFP* persistent idiopathic facial pain, *PTN* painful trigeminal neuropathy, *QS* quality score, *TMD* temporomandibular disorder, *TN* trigeminal neuralgia, *VBM* voxel-based morphometry, *W* women.

[^4]: Abbreviations: *ACC* anterior cingulate cortex, *aINS* anterior insular cortex, *aMCC* anterior mid-cingulate cortex, *bilat* bilateral, *BMS* burning mouth syndrome, *Cereb* cerebellum, *CN* caudate nucleus, *COFP* chronic orofacial pain, *CTN* classic trigeminal neuralgia, *dlPFC* dorsolateral prefrontal cortex, *DYS* dysgeusia, *Fus* fusiform gyrus*, FP* frontal polar, *GP* globus pallidus, *Hc* hippocampus, *Hypo* hypothalamus, *IFG* inferior frontal gyrus, *ITG* inferior temporal gyrus, *L* left, *M1* primary motor cortex, *MCC* middle cingulate cortex, *MCP* middle cerebellar peduncle, *MD* mediodorsal thalamus*, ML* medial lemniscus, *mOFC* medial orbitofrontal cortex, *mPFC* medial prefrontal cortex, *MTG* middle temporal gyrus, *NAc* nucleus accumens, *OFC* orbitofrontal cortex, *pACC* pregenual anterior cingulate cortex, *ParaHc* parahippocampal gyrus, *PCC* posterior cingulate cortex, *PCL* paracentral lobule, *PCu* precuneus, *PFC* prefrontal cortex, *pINS* posterior insular cortex, *PIFP* persistent idiopathic facial pain, *PMC* premotor cortex, *pre-SMA* pre supplementary motor area, *PTN* painful trigeminal neuropathy, *Pu* putamen, *R r*ight, *S1* primary somatosensory cortex, *S2* secondary somatosensory cortex, *sACC* subgenual anterior cingulate cortex, *SMA* supplementary motor area, *SPL* superior parietal lobule, *STG* superior temporal gyrus, *Thal* thalamus, *Ti* inferior temporal area, *TMD* temporomandibular disorder, *TN* trigeminal neuralgia, *VP* ventral posterior thalamus, *VL* ventral lateral thalamus, *vlPFC* ventrolateral prefrontal cortex, *VMN* trigeminal motor nucleus, *VMSN* trigeminal sensory nucleus, VS ventral striatum.

[^5]: Abbreviations: *BMS* burning mouth syndrome, *COFP* chronic orofacial pain, *CTN* classical trigeminal neuralgia, *fALFF* fractional apitude of low-frequency fluctuation, *fMRI* functional magnetic resonance imaging, *ITN* idiopathic trigeminal neuralgia, *M* men, *NP* neuropathic pain, *QS* quality score, *R* right, *ReHo* regional homogeneity*, TMD* temporomandibular disorder, *W* women.

[^6]: Graded Chronic Pain Scale of 52% of patients.

[^7]: Stimulus intensity: Labeled magnitude scale (0--100; 0 being "felt nothing" and 100 being "most intense vibration imaginable").

[^8]: Abbreviations: *A1* primary auditory cortex, *aINS* anterior insular cortex, *aMCC* anterior mid-cingulate cortex, *Amyg* amygdala, *bilat* bilateral, *BMS* burning mouth syndrome, *Cereb* cerebellum, *CN* caudate nucleus, *CTN* classic trigeminal neuralgia, *COFP* chronic orofacial pain, *Cu* cuneus, *dlPFC* dorsolateral prefrontal cortex, *dlPons* dorsolateral pons, *dpINS* dorsal posterior insular cortex, *fALFF* fractional aptitude of low-frequency fluctuation, *Fus* fusiform gyrus, *GP* globus pallidus, *IPL* inferior parietal lobule, *ITG* inferior temporal gyrus, *ITN* idiopathic trigeminal neuralgia, *L* left, *latFP* lateral frontal polar, *M1* primary motor cortex, *MCC* mid-cingulate cortex, *MD* mediodorsal thalamus, *mFP* medial frontal pole, *mid lNS* mid insular cortex, *MOG* middle occipital gyrus, *MTG* middle temporal gyrus, *OFC* orbitofrontal cortex, *pACC* pregenual anterior cingulate cortex, *ParaHc* parahippocampal gyrus, *PCC* posterior cingulate cortex, *PCu* precuneus, *PFC* prefrontal cortex, *pINS* posterior insular cortex, *PMCv* ventral premotor cortex, *PT* planum temporale, *PTN* painful trigeminal neuropathy, *Pu* putamen, *R* right, *ReHo* regional homogeneity, *RSC* rostral splenial cortex, *S1* primary somatosensory cortex, *S2* secondary somatosensory cortex, *sACC* subgenual anterior cingulate cortex, *SFG* superior frontal gyrus, *SMA* supplementary motor area, *SPL* superior parietal lobule, *STn* spinal trigeminal nucleus, *STN* subthalamic nucleus, *SPL* superior parietal lobule, *TPJ* temporoparietal joint, *Thal* Thalamus, *TMD* temporomandibular disorder, *TP* temporal pole*, V2* secondary visual cortex, *VP* ventral posterior thalamus, *VL* ventral lateral thalamus.

[^9]: ALE meta-analytic results of functional experimental pain studies (*n* = 12), significant at a cluster-corrected *p* \< .05 and cluster-forming threshold of *p* \< .005.

[^10]: Abbreviations: *aINS* anterior insular cortex, *ALE* activation likelihood estimation, *BA* Brodmann area, *L* left, *M1* primary motor cortex, *MNI* Montreal Neurological Institute, *mid INS* mid insular cortex, *pINS* posterior insular cortex, *pMCC* posterior mid-cingulate cortex, *PPC* posterior parietal cortex, *R* right, *S1* primary somatosensory cortex, *S2* secondary somatosensory cortex, *SMA* supplementary motor area, *STG* superior temporal gyrus.

[^11]: ALE meta-analytic results of structural COFP (*n* = 10) and functional studies (*n* = 8), significant at a cluster-corrected *p* \< .05 and cluster-forming threshold of *p* \< .005.

[^12]: Abbreviations: *ALE* activation/anatomical likelihood estimation, *COFP* chronic orofacial pain, *GMV/GMC* grey matter volume/grey matter concentration, *MNI* Montreal Neurological Institute, *pINS* posterior insular cortex.
